‘The Man Who Hated Women’ Is Mostly About the Women He Hated
By Jennifer Szalai,
New York Times
| 07. 12. 2021
“The Man Who Hated Women,” the arresting title of Amy Sohn’s new book, would have been more fitting if the book were truly about the man who hated women. But Sohn’s narrative is less about Anthony Comstock — the self-styled moral crusader and chief architect of the Comstock Act of 1873, which made it a federal offense to send “obscene, lewd or lascivious” material through the mail — than it is about the targets of his hatred, the women themselves.
Aside from offering a few perfunctory biographical details, Sohn mostly depicts Comstock as a nuisance or a cartoon villain — a pathetically obsessed figure who pops up now and again to make life horrendously difficult for the people he pursued. She earnestly pronounces him “the man who did more to curtail women’s rights than anyone else in American history.” More than anyone? Is she sure about that?
Sohn, the author of several dishy novels and a former columnist about sex and relationships for New York Press and New York magazine, doesn’t try to present Comstock as anything more...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...